The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...

Please provide your email address to receive an email when new articles are posted on . Become familiar with antibody-mediated myelin oligodendrocyte glycoprotein and neuromyelitis optica spectrum ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

The study looked at the potential benefits of cataract surgery in patients with a prior diagnosis of optic neuropathy. Patients with and without optic neuropathies showed significant improvement in ...

Thinking about mistakes, especially medical mistakes, is uncomfortable. It is certainly more enjoyable to read about a promising new therapy than to scrutinize the reasons that medical mistakes are ...

Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...